Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBGraft: Gene Therapy for RDEB
NCT04186650Phase 2Active, not recruiting
- Sponsor
- Inserm
- Start
- Jan 2020
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Retroviral Vectors, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of COL7A1-SIN retroviral vector in Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by Inserm. Primary endpoint: Safety of grafting SIN RV-mediated COL7A1 gene-modified autologous skin equivalent at 12 months. Started Jan 2020; status: active, not recruiting.
02
Drugs
COL7A1-SIN retroviral vector
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on NCT04186650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04186650.